Woodline Partners LP Lyell Immunopharma, Inc. Transaction History

Woodline Partners LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$5.54 - $8.27 $114,899 - $171,519	20,740 New	20,740 $152,000
Q2 2022 Aug 15, 2022	SELL	$3.68 - $6.8 $742,598 - $1.37 Million	-201,793 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$7.13 - $15.19 $29,069 - $61,929	-4,077 Reduced 1.98%	201,793 $1.56 Million
Q3 2021 Nov 15, 2021	SELL	$11.0 - $17.95 $3.23 Million - $5.27 Million	-293,689 Reduced 58.79%	205,870 $3.05 Million
Q2 2021 Aug 16, 2021	BUY	$15.99 - $16.89 $7.99 Million - $8.44 Million	499,559 New	499,559 $8.11 Million

121

142M

18.1K

200

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $151M
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.